➤ Physical and chemical incompatibility information often is difficult to evaluate and incorporate into clinical practice.
➤ Review of drug compatibilities and stabilities with commonly used 5-HT 3 receptor antagonists will prevent administration complications.
➤ Nurses' knowledge of compatibilities can minimize the need for multiple venous access sites.
Viki Longfield, RN, MSN, AOCN ® Purpose/Objectives: To compare stability and compatibility among the 5-HT 3 antiemetics in multidrug cytotoxic regimens.
Data Sources: Published articles, product-prescribing information, and direct communication with manufacturers.
Data Synthesis: Stability and compatibility of ondansetron and granisetron with a variety of other agents used in the oncology setting generally are similar. Granisetron is compatible with all tested Y-site drugs; ondansetron is not compatible with amsacrine or fluorouracil. Information for dolasetron is not as readily available; therefore, comparisons are difficult to make.
Conclusion: Although 5-HT 3 receptor antagonists have made a significant impact in decreasing severe emesis, administration of complex regimens can be confusing at best for nurses because of the lack of compatibility data. By partnering with pharmacists, nurses can develop administration guidelines to minimize complications and improve outcomes.
Implications for Nursing: To maximize patients' outcomes, oncology nurses must be knowledgeable about stability and compatibility of complex multidrug regimens that include the commonly used 5-HT 3 receptor antagonist antiemetics.
Goal for CE Enrollees:
To further enhance nurses' knowledge regarding compatibility and stability of 5-HT 3 receptor antagonists.
Objectives for CE Enrollees:
On completion of this CE, the participant will be able to 1. Discuss the stability and compatibility of 5-HT 3 receptor antagonist antiemetics in polyvinyl chloride containers. 2. Discuss the stability and compatibility of 5-HT 3 receptor antagonist antiemetics at Y-sites. 3. Discuss the nursing implications in the administration of multidrug regimens including the 5-HT 3 receptor antagonists.
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